Coya Therapeutics, Inc.

The momentum for this stock is not very good. Coya Therapeutics, Inc. is not a good value stock. Coya Therapeutics, Inc. is not a good growth stock. Coya Therapeutics, Inc. is not very popular among insiders. Tradey thinks it is not wise to invest in Coya Therapeutics, Inc..

News

Coya Therapeutics to Present at Upcoming Healthcare Conferences

Business Wire Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that CEO...\n more…

Coya Therapeutics promotes recent C-suite hire to CEO

Bizjournals.com - Health Care News Coya Therapeutics, which is developing drugs for Alzheimer's and ALS, promoted a leader who joined the company last year.\n more…

Coya Therapeutics CEO Howard Berman to leave role, Arun Swaminathan to succeed

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Coya Therapeutics Promotes Arun Swaminathan Ph.D. to Chief Executive Officer Effective November 1st, 2024

Coya Therapeutics, Inc. Forecasted to Post FY2024 Earnings of ($1.17) Per Share (NASDAQ:COYA)

Zolmax Coya Therapeutics, Inc. (NASDAQ:COYA - Free Report) - Equities research analysts at Chardan Capital raised their FY2024 earnings estimates for shares of Coya Therapeutics in a research report...\n more…

Brokers Issue Forecasts for Coya Therapeutics, Inc.'s FY2025 Earnings (NASDAQ:COYA)

Zolmax Coya Therapeutics, Inc. (NASDAQ:COYA - Free Report) - Research analysts at Chardan Capital issued their FY2025 earnings estimates for Coya Therapeutics in a research report issued to clients and...\n more…